{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"REGENXBIO Inc."},"Symbol":{"label":"Symbol","value":"RGNX"},"Address":{"label":"Address","value":"9804 MEDICAL CENTER DRIVE,SUITE 210, ROCKVILLE, Maryland, 20850, United States"},"Phone":{"label":"Phone","value":"+1 240 552-8181"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa)."},"CompanyUrl":{"label":"Company Url","value":"https://www.regenxbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Curran M. Simpson","title":"President, Chief Executive Officer & Director"},{"name":"Jerome W. Jackson","title":"Vice President-Information Technology"},{"name":"Olivier Danos","title":"Chief Scientific Officer & EVP"},{"name":"Stephen Pakola","title":"Chief Medical Officer & EVP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}